Tag: FDA approvals for neuroendocrine tumors
![Lu 177](https://www.carcinoid.org/wp-content/uploads/2016/05/Lu-177-300x300.jpg)
FDA Approves LUTATHERA® for Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
January 26, 2018
BREAKING NEWS: On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors …
READ MORE